1-Methyl-1,2,3,4-tetrahydroisoquinoline and established uncompetitive NMDA receptor antagonists induce tolerance to excitotoxicity

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1041-1050

  Kuszczyk, Magdalena ^a   Słomka, Marta ^a   Antkiewicz Michaluk, Lucyna ^b   Saliñska, Elzbieta ^a   Łazarewicz, Jerzy W ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Memantine; MK 801; Neurons; Neuroprotection; Post conditioning; Pre conditioning; Primary cultures; Tolerance

Indexed keywords

1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; DIZOCILPINE; GLUTAMIC ACID; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EXCITOTOXICITY; GRANULE CELL; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; RAT;

EID: 79551493065     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70366-2     Document Type: Article

References (62)

1. Abe K, Saitoh T, Horiguchi Y, Utsunomiya I, Taguchi K: Synthesis and neurotoxicity of tetrahydroisoquinoline derivatives for studying Parkinson's disease. Biol Pharm Bull, 2005, 28, 1355-1362.
2. Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA, Nicotera P: Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron, 1995, 15, 961-973.
3. Antkiewicz-Michaluk L, Karolewicz B, Romañska I, Michaluk J, Bojarski AJ, Vetulani J: 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol, 2003, 466, 263-269.
4. Antkiewicz-Michaluk L, Lazarewicz JW, Patsenka A, Kajta M, Zieminska E, Salinska E, Wasik A et al.: The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem, 2006, 97, 846-856.
5. Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, Romañska I, Lorenc-Koci E, Ohta S, Vetulani J: Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J Neurochem, 2001, 78, 100-108.
6. Antkiewicz-Michaluk L, Romañska I, Papla I, Michaluk J, Bakalarz M, Vetulani J, Krygowska-Wajs A, Szczudlik A: Neurochemical changes induced by acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline and salsolinol in dopaminergic structures of rat brain. Neuroscience, 2000, 96, 59-64.
7. Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romañska I, Bojarski A, Vetulani J: Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol, 2004, 7, 155-163.
8. Arundine M, Tymianski M: Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium, 2003, 34, 325-337.
9. Bond A, Lodge D, Hicks CA, Ward MA, O'Neill MJ: NMDA receptor antagonism, but not AMPA receptor antagonism attenuates induced ischaemic tolerance in the gerbil hippocampus. Eur J Pharmacol, 1999, 380, 91-99.
10. Burda J, Danielisová V, Némethová M, Gottlieb M, Kravcuková P, Domoráková I, Mechírová E, Burda R: Postconditioning and anticonditioning: possibilities to interfere to evoked apoptosis. Cell Mol Neurobiol, 2009, 29, 821-825.
11. Burda J, Danielisova V, Nemethova M, Gottlieb M, Matiasova M, Domorakova I, Mechirova E et al.: Delayed postconditionig initiates additive mechanism necessary for survival of selectively vulnerable neurons after transient ischemia in rat brain. Cell Mol Neurobiol, 2006, 26, 1141-1151.
12. Chen M, Lu TJ, Chen XJ, Zhou Y, Chen Q, Feng XY, Xu L et al.: Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke, 2008, 39, 3042-3048.
13. Collins MA, Neafsey EJ, Mukamal KJ, Gray MO, Parks DA, Das DK, Korthuis RJ: Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies. Alcohol Clin Exp Res, 2009, 33, 206-219.
14. Contestabile A: Cerebellar granule cells as a model to study mechanisms of neuronal apoptosis or survival in vivo and in vitro. Cerebellum, 2002, 1, 41-55. (Pubitemid 44133846)
15. Derwall M, Coburn M, Rex S, Hein M, Rossaint R, Fries M. Xenon: recent developments and future perspectives. Minerva Anestesiol, 2009, 75, 37-45.
16. Dickinson R, Peterson BK, Banks P, Simillis C, Martin JC, Valenzuela CA, Maze M, Franks NP: Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology. Anesthesiology, 2007, 107, 756-767. (Pubitemid 351325968)
17. Dirnagl U, Becker K, Meisel A: Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol, 2009, 8, 398-412.
18. Domoráková I, Mechírová E, Danková M, Danielisová V, Burda J: Effect of antioxidant treatment in global ischemia and ischemic postconditioning in the rat hippocampus. Cell Mol Neurobiol, 2009, 29, 837-844.
19. Duszczyk M, Gadamski R, Ziembowicz A, Danysz W, Lazarewicz JW: NMDA receptor antagonism does not inhibit induction of ischemic tolerance in gerbil brain in vivo. Neurotox Res, 2005, 7, 283-292.
20. Foster AC, Gill R, Woodruff GN: Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. J Neurosci, 1988, 8, 4745-4754. (Pubitemid 19015157)
21. Gray NM, Cheng BK, Mick SJ, Lair CM, Contreras PC: Phencyclidine-like effects of tetrahydroisoquinolines and related compounds. J Med Chem, 1989, 32, 1242-1248. (Pubitemid 19149975)
22. Hashimoto K, Tomitaka S, Bi Y, Narita N, Minabe Y, Iyo M: Rolipram, a selective phosphodiesterase type-IV inhibitor, prevents induction of heat shock protein HSP-70 and hsp-70 mRNA in rat retrosplenial cortex by the NMDA receptor antagonist dizocilpine. Eur J Neurosci, 1997, 9, 1891-1901. (Pubitemid 27429908)
23. Hondo H, Yonezawa Y, Nakahara K, Hirano M, Uchimura H, Tashiro N: Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res, 1994, 633, 337-342. (Pubitemid 24021280)
24. Hwang JY, Kim YH, Ahn YH, Wie MB, Koh JY: N-Methyl-D-aspartate receptor blockade induces neuronal apoptosis in cortical culture. Exp Neurol, 1999, 159, 124-130.
25. Kato H, Liu Y, Araki T, Kogure K: MK-801, but not anisomycin, inhibits the induction of tolerance to ischemia in the gerbil hippocampus. Neurosci Lett, 1992, 139, 118-121.
26. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, Handa N et al.: "Ischemic tolerance" phenomenon found in the brain. Brain Res, 1990, 528, 21-24.
27. Kotake Y, Taguchi R, Okuda K, Sekiya Y, Tasaki Y, Hirobe M, Ohta S: Neuroprotective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on cultured rat mesencephalic neurons in the presence or absence of various neurotoxins. Brain Res, 2005, 1033, 143-150.
28. Kotake Y, Tasaki Y, Makino Y, Ohta S, Hirobe M: 1-Benzyl-1,2,3,4- tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem, 1995, 65, 2633-2638.
29. Kuszczyk M, Gordon-Krajcer W, Lazarewicz JW: Homocysteine-induced acute excitotoxicity in cerebellar granule cells in vitro is accompanied by PP2A-mediated dephosphorylation of tau. Neurochem Int, 2009, 55, 174-180.
30. Lee JJ, Li L, Jung HH, Zuo Z: Postconditioning with isoflurane reduced ischemia-induced brain injury in rats. Anesthesiology, 2008, 108, 1055-1062.
31. Lipton SA: Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx, 2004, 1, 101-110.
32. Lipton SA: The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res, 2005, 2, 155-165.
33. Lorenc-Koci E, Śmiałowska M, Antkiewicz-Michaluk L, Gołembiowska K, Bajkowska M, Wolfarth S: Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats. Neuroscience, 2000, 95, 1049-1059.
34. Lovinger DM, White G, Weight FF: Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science, 1989, 243, 1721-1724.
35. Ludwig M, Hoesl CE, Höfner G, Wanner KT: Affinity of 1-aryl-1,2,3,4-tetrahydroisoquinoline derivatives to the ion channel binding site of the NMDA receptor complex. Eur J Med Chem, 2006, 41, 1003-1010.
36. Marini AM, Ueda Y, June CH: Intracellular survival pathways against glutamate receptor agonist excitotoxicity in cultured neurons. Intracellular calcium responses. Ann NY Acad Sci, 1999, 890, 421-437.
37. Miao B, Yin XH, Pei DS, Zhang QG, Zhang GY: Neuroprotective effects of preconditioning ischemia on ischemic brain injury through down-regulating activation of JNK1/2 via N-methyl-D-aspartate receptor-mediated Akt1 activation. J Biol Chem, 2005, 280, 21693-21699. (Pubitemid 40827815)
38. Nakamura T, Lipton SA: Emerging roles of S-nitrosylation in protein misfolding and neurodegenerative diseases. Antioxid Redox Signal, 2008, 10, 87-101.
39. Obrenovitch TP: Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev, 2008, 88, 211-247.
40. Patsenka A, Antkiewicz-Michaluk L: Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds, 1,2,3,4- tetrahydroisoquinoline alkaloids. Pol J Pharmacol, 2004, 56, 727-734.
41. Pietraszek M, Michaluk J, Romañska I, Wa̧sik A, Gołembiowska K, Antkiewicz-Michaluk L: 1-Methyl-1,2,3,4- tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat. Neurotox Res, 2009, 16, 390-407.
42. Pignataro G, Meller R, Inoue K, Ordonez AN, Ashley MD, Xiong Z, Gala R, Simon RP: In vivo and in vitro characterization of a novel neuroprotective strategy for stroke: ischemic postconditioning. J Cereb Blood Flow Metab, 2008, 28, 232-241.
43. Puisieux F, Deplanque D, Bulckaen H, Maboudou P, Gelé P, Lhermitte M, Lebuffe G, Bordet R: Brain ischemic preconditioning is abolished by antioxidant drugs but does not up-regulate superoxide dismutase and glutathion peroxidase. Brain Res, 2004, 1027, 30-37.
44. Prehn JH, Lippert K, Krieglstein J: Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury? Eur J Pharmacol, 1995, 292, 179-189.
45. Rehni AK, Singh N: Role of phosphoinositide 3-kinase in ischemic postconditioning-induced attenuation of cerebral ischemia-evoked behavioral deficits in mice. Pharmacol Rep, 2007, 59, 192-198.
46. Rothman SM, Thurston JH, Hauhart RE: Delayed neurotoxicity of excitatory amino acids in vitro. Neuroscience, 1987, 22, 471-480.
47. Scartabelli T, Gerace E, Landucci E, Moroni F, Pellegrini-Giampietro DE: Neuroprotection by group I mGlu receptors in a rat hippocampal slice model of cerebral ischemia is associated with the PI3K-Akt signaling pathway: a novel postconditioning strategy? Neuropharmacology, 2008, 55, 509-516.
48. Schmidt CJ, Fadayel GM: Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Ther, 1996, 277, 1541-1549.
49. B receptors: cerebellar granule cells as a model system. Neurochem Int, 1999, 34, 373-377.
50. Schousboe A, Drejer J, Hansen GH, Meier E: Cultured neurons as model systems for biochemical and pharmacological studies on receptors for neurotransmitter amino acids. Dev Neurosci, 1985, 7, 252-262.
51. Tasaki Y, Makino Y, Ohta S, Hirobe M: 1-Methyl-1,2,3,4- tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities. J Neurochem, 1991, 57, 1940-1943.
52. Testa CM., Sherer TB., Greenamyre JT: Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res, 2005, 134, 109-118.
53. Tremblay R, Chakravarthy B, Hewitt K, Tauskela J, Morley P, Atkinson T, Durkin JP: Transient NMDA receptor inactivation provides long-term protection to cultured cortical neurons from a variety of death signals. J Neurosci, 2000, 20, 7183-7192.
54. Vetulani J, Antkiewicz-Michaluk L, Nalepa I, Sansone M: A possible physiological role for cerebral tetrahydroisoquinolines. Neurotox Res, 2003, 5, 147-155.
55. Wang JY, Shen J, Gao Q, Ye ZG, Yang SY, Liang HW, Bruce IC et al.: Ischemic postconditioning protects against global cerebral ischemia/reperfusion- induced injury in rats. Stroke, 2008, 39, 983-990.
56. Wang Q, Sun AY, Simonyi A, Kalogeris TJ, Miller DK, Sun GY, Korthuis RJ: Ethanol preconditioning protects against ischemia/reperfusion-induced brain damage: role of NADPH oxidase-derived ROS. Free Radic Biol Med, 2007, 43, 1048-1060.
57. Willis CJ, Ray DE: Antioxidants attenuate MK-801-induced cortical neurotoxicity in the rat. Neurotoxicology, 2007, 28, 161-167.
58. Wrang ML, Diemer NH: MK-801 does not prevent development of ischemic tolerance in rat brain. Neuroreport, 2004, 15, 1151-1155.
59. Xing B, Chen H, Zhang M, Zhao D, Jiang R, Liu X, Zhang S: Ischemic postconditioning inhibits apoptosis after focal cerebral ischemia/reperfusion injury in the rat. Stroke, 2008, 39, 2362-2369.
60. Yin XH, Zhang QG, Miao B, Zhang GY: Neuroprotective effects of preconditioning ischaemia on ischaemic brain injury through inhibition of mixed-lineage kinase 3 via NMDA receptor-mediated Akt1 activation. J Neurochem, 2005, 93, 1021-1029. (Pubitemid 40695761)
61. Zhao H: Ischemic postconditioning as a novel avenue to protect against brain injury after stroke. J Cereb Blood Flow Metab, 2009, 29, 873-885.
62. Zhao H, Sapolsky RM, Steinberg GK: Interrupting reperfusion as a stroke therapy: ischemic postconditioning reduces infarct size after focal ischemia in rats. J Cereb Blood Flow Metab, 2006, 26, 1114-1121.